Osimertinib mesylate
Osimertinib mesylate is an orally active, irreversible third-generation EGFR inhibitor designed to target the T790M resistance mutation in non-small cell lung cancer. It is widely used in both in vitro biochemical assays and in vivo xenograft models to study resistance mechanisms and evaluate therapeutic efficacy against EGFR-mutant tumors.
Product Specifications
CAS Number
1421373-66-1
Product Name Alternative
Tumor xenograft model, H1975, Epidermal growth factor receptor, EGFR, EGFR (L858R), EGFR (L858R/T790M), ErbB-1, HER1, Inhibitor, Mereletinib mesylate, Mereletinib Mesylate, Mereletinib, inhibit, Osimertinib Mesylate, Osimertinib mesylate, Osimertinib, PC-9, AZD-9291 mesylate, AZD-9291, AZD9291, AZD9291 Mesylate, AZD-9291 Mesylate, AZD 9291, AZD 9291 Mesylate, cancer, Ba/F3 cells
Field of Research
Cardiovascular Research, Pharmacology & Drug Discovery, Signal Transduction
Purity
98.65% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (1.68 mM) ; DMSO:14 mg/mL (23.5 mM) ; H2O:20 mg/mL (33.57 mM)
Smiles
CS (O) (=O) =O.COc1cc (N (C) CCN (C) C) c (NC (=O) C=C) cc1Nc1nccc (n1) -c1cn (C) c2ccccc12
Molecular Formula
C29H37N7O5S
Molecular Weight
595.71
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
129398-APC 100 µL
MAPK12 (Mitogen-activated Protein Kinase 12, MAPK 12, MAP Kinase 12, PRKM12, Extracellular Signal-regulated Kinase 6, ERK6, ERK-6, Mitogen-activated Protein Kinase p38 gamma, MAP Kinase p38 gamma, P38gamma, Stress-activated Protein Kinase 3, SAPK3, SAPK-3) (APC)
Sign In for Pricing
View Details 
